1. Home
  2. ACOG vs KROS Comparison

ACOG vs KROS Comparison

Compare ACOG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.34

Market Cap

185.1M

Sector

N/A

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$10.99

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
KROS
Founded
2000
2015
Country
Canada
United States
Employees
71
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.1M
206.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACOG
KROS
Price
$8.34
$10.99
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$16.00
$21.86
AVG Volume (30 Days)
54.8K
313.0K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
146.00
EPS
N/A
N/A
Revenue
N/A
$243,864,000.00
Revenue This Year
$139.22
N/A
Revenue Next Year
$134.48
$2,751.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$9.69
52 Week High
$10.59
$22.55

Technical Indicators

Market Signals
Indicator
ACOG
KROS
Relative Strength Index (RSI) 70.71 49.58
Support Level $5.27 $10.83
Resistance Level N/A $11.55
Average True Range (ATR) 0.57 0.61
MACD 0.07 -0.00
Stochastic Oscillator 82.05 36.34

Price Performance

Historical Comparison
ACOG
KROS

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: